Compare Bristol-Myers Squibb Co (BMY) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Snowflake Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.73 (market cap $129.94B), while Snowflake Inc trades at $334.88 (market cap $116.01B). The key difference: Bristol-Myers Squibb Co and Snowflake Inc are close in size by market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals.
| BMY | SNOW | |
|---|---|---|
Market Cap | $129.94B | $116.01B |
Sector | Health | Technology |
52-Week High | $65.89 | $334.70 |
52-Week Low | $42.60 | $121.11 |
Enterprise Value | $163.92B | $115.82B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Snowflake trades at $339.00, up 1.28% with bullish technical signals and strong analyst support (81% buy ratings). The company shows impressive revenue growth from $1.2B in 2022 to $3.6B in 2025, though remains unprofitable with a -23.79% net margin. Recent earnings beats and AI platform expansions drive optimism, but premium valuation at 22.66x P/S ratio presents risk.
Outlook remains positive with AI data cloud leadership and 30% revenue growth guidance, but investors face valuation concerns and persistent losses. Key catalysts include Q2 2026 earnings on September 2nd and enterprise AI adoption trends. The stock trades near resistance at $341 with consensus price target of $302.18 suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
